This chapter discusses the molecular pharmacology of antiresorptive therapy for osteoporosis. Estrogen is one of the main therapeutic modalities for treating and preventing post-menopausal bone loss. It reduces both cortical and trabecular bone loss in the axial as well as the peripheral skeleton. In...
Harris ST, Watts NB, Genant HK,et al.:For the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and non-vertbral fractures in women with postmenopausal osteoporosis: a randomized controlled trial.JAMA1999,282:1344–1352. ArticlePubMedCASGo...
Poxleitner P, Steybe D, Kroneberg P et al (2020) Tooth extractions in patients under antiresorptive therapy for osteoporosis: primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis...
Hellstein JW, Adler RA, Edwards B, et al: Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommen- dations from the American Dental Association Council on Sci- entific Affairs. J Am Dent Assoc 142:1243, 2011...
This review addresses the critical issue of risk management in patients with osteoporosis who require dentoalveolar surgery while undergoing anti-resorptive therapy. Dental practitioners should be aware of these risks; however, they should not refuse treatment based solely on them. This review discusses...
Antiresorptive agents slow remodelling, thereby reducing the reversible deficit in bone volume, resulting in an early rapid increase in BMD, but the irreversible deficit in bone volume responsible for microstructural deterioration is not corrected. Restoring bone microstructure requires anabolic therapy, whi...
PubMed Medline, Embase, LILACS, and reference lists of potential eligible studies. Prospective control trials, cohort and case series analysing results on at least 20 patients treated with ARD therapy (IV or orally). Studies reporting a protocol used for
The most well studied combination therapy approach has been the coadministration of bisphosphonates and parathyroid hormone (PTH) analogs. Additionally, teriparatide monotherapy increased lumbar spine trabecular volumetric bone mineral density (vBMD), assessed by QCT, more than combination treatment or ...
Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep. 2008;6:24-30.Bilezikian, J. P. (2008), `Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window', Current Osteoporosis Reports, 6, pp 24-30....
Osteoporosis the mandible or maxilla that has not healed over six to eight weeks, often occurring after oral surgery or a tooth extraction. About 95% of reported cases have been in cancer patients receiving prolonged high doses of IV bisphosphonates. It is anEM Lewiecki...